Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROMETH VC PLAIN vs DI-METREX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, blocking allergic reactions; it also has anticholinergic, antiemetic, sedative, and local anesthetic effects.
Combination of diphenhydramine (H1-antagonist) and pseudoephedrine (alpha-1 agonist). Diphenhydramine blocks histamine at H1 receptors, reducing allergic symptoms; pseudoephedrine causes vasoconstriction via alpha-1 adrenergic receptors, relieving nasal congestion.
FDA: Allergic conditions (rhinitis, urticaria, pruritus), motion sickness, nausea/vomiting, preoperative sedation, postoperative pain control (adjunct),Off-label: Nausea in pregnancy (morning sickness), vertigo, sedation in pediatric procedures
Symptomatic relief of seasonal allergies,Upper respiratory tract allergies,Nasal congestion,Sinus congestion
Adults: 1-2 tablets (each containing Promethazine 6.25 mg and Phenylephrine 5 mg) orally every 4-6 hours; maximum 12 tablets per day.
4 mg orally once daily, increased to a maximum of 8 mg once daily if needed.
Promethazine: terminal half-life 9-16 hours (mean 12 hours) in adults; longer in elderly (13.5-18 hours) and in hepatic impairment. Phenylephrine: half-life 2-3 hours.
The terminal elimination half-life is approximately 12 hours, requiring twice-daily dosing for steady-state concentrations.
Primarily hepatic metabolism via CYP2D6 and other pathways; metabolites include promethazine sulfoxide and N-demethylated derivatives.
Diphenhydramine: extensively metabolized via CYP2D6 to inactive metabolites; pseudoephedrine: partially metabolized in liver via N-demethylation to active metabolite (norpseudoephedrine) and excreted unchanged in urine.
Primarily renal; promethazine is excreted in urine as unchanged drug (approximately 6%) and as metabolites (promethazine sulfoxide and N-demethylpromethazine); less than 1% excreted in feces. Phenylephrine is primarily metabolized by MAO and COMT; renal excretion of metabolites and unchanged drug (about 16%).
Renal excretion accounts for approximately 70% of elimination as unchanged drug and metabolites; biliary/fecal excretion accounts for the remaining 30%.
Promethazine: approximately 93% bound to plasma proteins (mainly albumin). Phenylephrine: approximately 95% bound to plasma proteins (mainly albumin).
Approximately 85% bound to serum albumin.
Promethazine: Vd 5-17 L/kg (mean ~12 L/kg), indicating extensive tissue distribution. Phenylephrine: Vd 4-5 L/kg, also widely distributed.
Vd is 0.8 L/kg, indicating distribution into total body water and some tissue binding.
Oral promethazine: approximately 25% due to extensive first-pass metabolism. Intramuscular: nearly 100%. Rectal: approximately 70% of oral. Phenylephrine: oral bioavailability is low (about 38%) due to first-pass metabolism by MAO in gut and liver.
Oral bioavailability is 90% due to minimal first-pass metabolism.
No specific guidelines; use with caution in renal impairment (Cr Cl <30 m L/min) due to potential accumulation of promethazine; consider dose reduction or extended intervals.
GFR 30-50 m L/min: 2 mg once daily. GFR <30 m L/min: not recommended.
Child-Pugh Class A-C: Use with caution; reduce dose or avoid in severe hepatic impairment (Child-Pugh Class C) due to decreased metabolism of promethazine.
Child-Pugh A: no adjustment. Child-Pugh B: 2 mg once daily. Child-Pugh C: not recommended.
Children aged 6-12 years: 1 tablet orally every 4-6 hours; maximum 6 tablets per day. Not recommended for children under 6 years due to risk of respiratory depression.
Not established; contraindicated in children under 12 years.
Elderly patients: Initiate at lower doses (e.g., 1 tablet orally every 6-8 hours) and titrate carefully; monitor for anticholinergic effects, sedation, and orthostatic hypotension.
Start at 2 mg once daily; titrate cautiously due to increased risk of hypotension and cognitive effects.
Promethazine should not be used in children younger than 2 years due to risk of respiratory depression, including fatalities. Use in children aged 2+ with caution. Not for intra-arterial or subcutaneous injection (risk of severe tissue injury).
Not applicable (no FDA boxed warning).
Risk of respiratory depression (especially in children, elderly, or with CNS depressants); use caution in asthma, sleep apnea, respiratory insufficiency. May impair cognitive/motor function; avoid alcohol. Extrapyramidal symptoms (rare). Caution in glaucoma, prostatic hyperplasia, urinary retention. Use in pregnancy (only if clearly needed).
Do not use in patients with severe hypertension or coronary artery disease; caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and MAOI use; avoid exceeding recommended dose due to risk of serious cardiovascular events; may cause drowsiness or excitability in children.
Hypersensitivity to promethazine or phenothiazines; children <2 years; comatose patients; CNS depression (e.g., alcohol, barbiturates); Reye's syndrome (avoid in children with viral illness due to risk of Reye's? – actually contraindicated in patients with suspected Reye's). Also contraindicated for intra-arterial or subcutaneous injection.
Hypersensitivity to diphenhydramine, pseudoephedrine, or any component; severe hypertension; severe coronary artery disease; concurrent MAOI therapy or within 14 days; narrow-angle glaucoma; urinary retention; during or within 2 weeks of MAOI use.
No clinically significant food interactions. However, taking with food may reduce gastrointestinal upset. Avoid grapefruit juice as it may theoretically increase sedation.
Avoid alcohol entirely. Folic acid supplementation is often prescribed to reduce side effects; do not take any other folate supplements without approval. Caffeine may slightly increase absorption, but no specific dietary restrictions. Maintain adequate hydration to help prevent kidney toxicity.
First trimester: Avoid. Inadequate studies; animal studies not sufficient. Second/third trimester: Use only if clearly needed; may cause neonatal respiratory depression, irritability, and tremors if used near term.
DI-METREX (metformin) is classified as FDA Pregnancy Category B. First trimester: No increased risk of major congenital anomalies observed in human studies; some studies suggest reduced risk of neural tube defects in women with PCOS. Second and third trimesters: Risk of neonatal hypoglycemia and macrosomia reduced compared to untreated diabetes; no evidence of teratogenicity. Overall, benefits of glycemic control outweigh potential risks.
Promethazine is excreted into breast milk in small amounts; M/P ratio unknown. Caution suggested; avoid in infants with apnea, respiratory issues, or in mothers of preterm infants.
Metformin is excreted into breast milk in small amounts with an M/P ratio (milk-to-plasma ratio) of approximately 0.35. Infant exposure is estimated at 0.2-1% of maternal weight-adjusted dose. No adverse effects reported in breastfed infants; however, caution in premature infants or those with renal impairment.
No standard dose adjustment required during pregnancy. Use lowest effective dose; monitor for increased sedation and anticholinergic effects due to physiological changes.
No routine dose adjustment recommended. However, as pregnancy progresses, renal function decreases and volume of distribution increases, which may reduce metformin clearance. Dose should be titrated to glycemic targets, up to a maximum of 2500 mg/day in divided doses. Monitor renal function and consider dose reduction if e GFR < 30 m L/min/1.73 m².
Promethazine is a phenothiazine derivative with antihistamine, antiemetic, sedative, and anticholinergic properties. Administer deep IM if parenteral route required; avoid intra-arterial or subcutaneous injection due to risk of severe tissue damage. Monitor for extrapyramidal symptoms in children and elderly. Use with caution in patients with asthma, COPD, or sleep apnea due to respiratory depression risk. Do not use in children <2 years due to risk of fatal respiratory depression.
DI-METREX (methotrexate) has a long half-life; monitor for cumulative toxicity. Administer folic acid supplementation to reduce gastrointestinal and hematologic side effects. Use with caution in patients with ascites or pleural effusions, as drug accumulation can occur. Premedication with NSAIDs increases methotrexate toxicity. Always check liver function tests and renal function before each dose.
Do not drive or operate heavy machinery until you know how this medication affects you, as it can cause drowsiness and dizziness.,Avoid alcohol and other central nervous system depressants while taking this medication.,Take exactly as prescribed; do not exceed recommended dose or duration.,Contact your healthcare provider if you experience difficulty breathing, involuntary muscle movements, or signs of jaundice (yellowing of skin/eyes).
Take methotrexate exactly as prescribed, usually once weekly, not daily. Serious harm can occur if taken daily.,Avoid alcohol completely to reduce liver damage risk.,Report any unusual bleeding, bruising, fever, mouth sores, or persistent cough immediately.,Do not take any other medications, including over-the-counter and herbal products, without first consulting your doctor.,Use effective contraception; methotrexate can cause severe birth defects.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROMETH VC PLAIN vs DI-METREX, answered by our medical review team.
PROMETH VC PLAIN is a Antihistamine-decongestant combination that works by Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, blocking allergic reactions; it also has anticholinergic, antiemetic, sedative, and local anesthetic effects.. DI-METREX is a Antihistamine-Decongestant that works by Combination of diphenhydramine (H1-antagonist) and pseudoephedrine (alpha-1 agonist). Diphenhydramine blocks histamine at H1 receptors, reducing allergic symptoms; pseudoephedrine causes vasoconstriction via alpha-1 adrenergic receptors, relieving nasal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROMETH VC PLAIN and DI-METREX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROMETH VC PLAIN is: Adults: 1-2 tablets (each containing Promethazine 6.25 mg and Phenylephrine 5 mg) orally every 4-6 hours; maximum 12 tablets per day.. The standard adult dose of DI-METREX is: 4 mg orally once daily, increased to a maximum of 8 mg once daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROMETH VC PLAIN and DI-METREX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROMETH VC PLAIN is classified as Category C. First trimester: Avoid. Inadequate studies; animal studies not sufficient. Second/third trimester: Use only if clearly needed; may cause neonatal respiratory depression, irritabili. DI-METREX is classified as Category C. DI-METREX (metformin) is classified as FDA Pregnancy Category B. First trimester: No increased risk of major congenital anomalies observed in human studies; some studies suggest re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.